A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, 2-arm crossover study comparing tivozanib hydrochloride and
sunitinib in subjects with metastatic RCC who have received no prior systemic therapy for
Renal Cell Carcinoma (RCC).